½ÃÀ庸°í¼­
»óǰÄÚµå
1381667

¼¼°èÀÇ ¾à¹°Àü´Þ ±â±â ½ÃÀå ±Ô¸ð Á¶»ç ¹× ¿¹Ãø : Åõ¿© °æ·Îº°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° ºÐ¼®(2023-2030³â)

Global Drug Delivery Devices Market Size study & Forecast, by Route of Administration, by Application, by End User and Regional Analysis, 2023-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Bizwit Research & Consulting LLP | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¾à¹°Àü´Þ ±â±â´Â ½Å¾à ¹ß°ß ¹× °³¹ß °úÁ¤¿¡¼­ »ç¿ëµÇ´Â ±â¼ú µµ±¸ ¹× ÀåºñÀÔ´Ï´Ù.

ÀÌ·¯ÇÑ ±â±âµéÀº Ç¥Àû ½Äº° ¹× °ËÁõ¿¡¼­ ¸®µå ÃÖÀûÈ­ ¹× ÀüÀÓ»ó½ÃÇè¿¡ À̸£±â±îÁö ½Å¾à °³¹ß ÆÄÀÌÇÁ¶óÀÎÀÇ ´Ù¾çÇÑ ´Ü°è¿¡¼­ ¿¬±¸ÀÚ¿Í °úÇÐÀÚµéÀ» Áö¿øÇϵµ·Ï ¼³°èµÆ½À´Ï´Ù. ¾à¹°Àü´Þ ±â±â ½ÃÀåÀÇ ¼ºÀå ¹è°æ¿¡´Â ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡, ¾à¹°Àü´Þ ±â±â¿¡ ´ëÇÑ R&D ÅõÀÚ Áõ°¡, ½Å¾à¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ µîÀÇ ¿äÀÎÀÌ ÀÖ½À´Ï´Ù.

¾Ï, ½ÉÇ÷°ü Áúȯ, ½Å°æ Áúȯ°ú °°Àº ¸¸¼º ÁúȯÀÇ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¾à¹°Àü´Þ ±â±â ½ÃÀåÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Áúº´À» Ä¡·áÇÒ ¼ö ÀÖ´Â È¿°úÀûÀÎ ¾à¹°ÀÌ ÇÊ¿äÇϸç, ÀÌ´Â ¾à¹°Àü´ÞÀåÄ¡ÀÇ ¼ö¿ä¸¦ °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ¸¸¼º ÁúȯÀÇ Áõ°¡·Î ÀÎÇØ Çõ½ÅÀûÀÎ ¾à¹°ÀÇ Çʿ伺ÀÌ ´ëµÎµÇ°í ÀÖÀ¸¸ç, ÀÌ´Â ½Å¾à °³¹ß¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡¿Í Á¤±³ÇÑ ¾à¹°Àü´Þ ±â±âÀÇ °³¹ß·Î À̾îÁö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀåÄ¡´Â ÀǾàǰ °³¹ß °úÁ¤ÀÇ È¿À²¼º°ú È¿°ú¸¦ Çâ»ó½ÃÄÑ ±Ã±ØÀûÀ¸·Î ¸¸¼º Áúȯ¿¡ ´ëÇÑ ´õ ³ªÀº Ä¡·á ¿É¼ÇÀ» Á¦°øÇÔÀ¸·Î½á ȯÀڵ鿡°Ô ÇýÅÃÀ» ÁÙ ¼ö ÀÖ½À´Ï´Ù. ±¹Á¦´ç´¢º´¿¬¸Í(International Diabetes Federation)Àº 2021³â ÀεµÀÇ ´ç´¢º´ ȯÀÚ ¼ö°¡ 7,419¸¸ 4,700¸íÀ¸·Î ¿¹»óµÇ¸ç, ÀÌ ¼öÄ¡´Â 2030³â±îÁö 9,297¸¸ 3,700¸íÀ¸·Î Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óÇß½À´Ï´Ù. ¶ÇÇÑ, ·Î¹öÆ® ¿ìµå Á¸½¼ Àç´ÜÀÇ º¸°í¼­¿¡ µû¸£¸é, ¹Ì±¹¿¡¼­´Â 2020³â 1¾ï 5,700¸¸ ¸íÀÇ ¸¸¼ºÁúȯ ȯÀÚ°¡ ¹ß»ýÇϸç, 2030³â¿¡´Â 1¾ï 7,100¸¸ ¸íÀ¸·Î ´Ã¾î³¯ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ, ±¹Á¦¾Ï¿¬±¸¼Ò(IARC)´Â 2021³â 190¸¸ ¸íÀ̾ú´ø ½Å±Ô ȯÀÚ°¡ 2020³â¿¡´Â Àü ¼¼°èÀûÀ¸·Î ¾à 2,750¸¸ ¸í¿¡ ´ÞÇÒ °ÍÀ¸·Î ÃßÁ¤Çϰí ÀÖ½À´Ï´Ù. ÀÌó·³ Àü ¼¼°èÀûÀ¸·Î ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡´Â ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Àü·«Àû ÀÌ´Ï¼ÅÆ¼ºêÀÇ ½ÇÇà°ú ½ÅÁ¦Ç° âÃâÀÇ È®´ë°¡ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2021³â 3¿ù ½ºÅÄÆ÷µå ´ëÇаú ³ë½ºÄ³·Ñ¶óÀ̳ª ´ëÇб³ äÇÃÈú Ä·ÆÛ½º(UNC)ÀÇ ¿¬±¸ÁøÀº 3D ÇÁ¸°ÆÃ ¹é½Å ÆÐÄ¡¸¦ °³¹ßÇÏ¿© ±âÁ¸ ¹é½Å Áֻ纸´Ù ´õ ³ªÀº ¿¹¹æ È¿°ú¸¦ Á¦°øÇÑ´Ù°í ¹àÇû½À´Ï´Ù. ÀÌ·¯ÇÑ Çõ½ÅÀûÀÎ ¾ÆÀÌÅÛÀÇ Åº»ýÀº ¾à¹°Àü´Þ Á¦Ç°ÀÇ »ç¿ëÀ» ÃËÁøÇÏ°í ½ÃÀå È®´ë¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ±â¼ú ¹ßÀüÀ» À§ÇÑ ÀÌ´Ï¼ÅÆ¼ºêÀÇ Áõ°¡, °³ÀÎÈ­ ÀÇ·áÀÇ ¹ßÀü, Á¤ºÎÀÇ À¯¸®ÇÑ ±ÔÁ¦ ¹× Á¤Ã¥Àº ½ÃÀå ¼ºÀå ±âȸ¸¦ âÃâÇϰí ÀÖÀ¸¸ç, BLA´Â 2023³â 4ºÐ±â ¸»±îÁö Á¦ÃâµÉ ¿¹Á¤ÀÔ´Ï´Ù. ÀÌ Á¦Ç°ÀÌ ¼º°øÀûÀ¸·Î Ãâ½ÃµÇ¸é ȯÀڵ鿡°Ô ¶Ç ´Ù¸¥ ¼±ÅñÇÀ» Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù. ±×·¯³ª ¾à¹°Àü´Þ ±â±âÀÇ ³ôÀº ºñ¿ëÀº 2023-2030³â ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» ÀúÇØÇϰí ÀÖ½À´Ï´Ù.

¾à¹°Àü´Þ ±â±â ¼¼°è ½ÃÀå Á¶»ç¿¡¼­ °í·ÁµÈ ÁÖ¿ä Áö¿ªÀº ¾Æ½Ã¾ÆÅÂÆò¾ç, ºÏ¹Ì, À¯·´, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÔ´Ï´Ù. ºÏ¹Ì´Â ÁÖ¿ä ½ÃÀå ÁøÀÔ ±â¾÷ÀÇ Á¸Àç, ¿¬±¸ °³¹ß Ȱµ¿¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡, ´Ù¾çÇÑ Áúº´ÀÇ À¯º´·ü Áõ°¡, ÀÌ Áö¿ªÀÇ ¾à¹° °³¹ß Ȱµ¿ Áõ°¡·Î ÀÎÇØ 2022³â ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù. ¹Ý¸é, ¾Æ½Ã¾ÆÅÂÆò¾çÀº ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡, ÀÇ·á ¹ßÀü, ¾à¹°Àü´Þ ±â±â Á¦Á¶¿¡ ´ëÇÑ Á¤ºÎÀÇ Àû±ØÀûÀÎ ³ë·Â, ÀÌ Áö¿ªÀÇ Á¦Ç° Ãâ½Ã Áõ°¡ µîÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ Å©°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ Á¶»çÀÇ ¸ñÀûÀº ÃÖ±Ù ¸î ³â°£ ´Ù¾çÇÑ ºÎ¹®°ú ±¹°¡ÀÇ ½ÃÀå ±Ô¸ð¸¦ ÆÄ¾ÇÇϰí ÇâÈÄ ¸î ³â°£ ½ÃÀå ±Ô¸ð¸¦ ¿¹ÃøÇÏ´Â °ÍÀÔ´Ï´Ù. ÀÌ º¸°í¼­´Â Á¶»ç ´ë»ó ±¹°¡ÀÇ »ê¾÷ÀÇ ÁúÀû, ¾çÀû Ãø¸éÀ» ¸ðµÎ Æ÷ÇÔÇϵµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù.

¶ÇÇÑ ½ÃÀåÀÇ ¹Ì·¡ ¼ºÀåÀ» ±ÔÁ¤ÇÏ´Â ÃËÁø¿äÀΰú °úÁ¦¿Í °°Àº Áß¿äÇÑ Ãø¸é¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ Á¤º¸µµ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ, ÁÖ¿ä ±â¾÷ÀÇ °æÀï »óȲ°ú Á¦Ç° Á¦°ø¿¡ ´ëÇÑ »ó¼¼ÇÑ ºÐ¼®°ú ÇÔ²² ÀÌÇØ°ü°èÀÚµéÀÌ ÅõÀÚÇÒ ¼ö ÀÖ´Â ¹Ì½ÃÀû ½ÃÀå¿¡¼­ÀÇ ÀáÀçÀû ±âȸµµ Æ÷ÇÔÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ¾à¹°Àü´Þ ±â±â ¼¼°è ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§

  • Á¶»ç ¸ñÀû
  • ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§
    • »ê¾÷ÀÇ ÁøÈ­
    • Á¶»ç ¹üÀ§
  • Á¶»ç ´ë»ó ¿¬µµ
  • ÅëÈ­ ȯ»êÀ²

Á¦3Àå ¾à¹°Àü´Þ ±â±â ¼¼°è ½ÃÀå ¿ªÇÐ

  • ¾à¹°Àü´Þ ±â±â ½ÃÀå ¿µÇ⠺м®(2020-2030³â)
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
      • ¸¸¼ºÁúȯ Áõ°¡
      • ¿¬±¸°³¹ß ÅõÀÚ Áõ°¡
      • ½Å¾à¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡
    • ½ÃÀå °úÁ¦
      • ¾à¹°Àü´ÞÀÇ °íºñ¿ë
    • ½ÃÀå ±âȸ
      • ±â¼ú Áøº¸¸¦ ÇâÇÑ ÀÌ´Ï¼ÅÆ¼ºê »ó½Â
      • ¸ÂÃãÇü ÀÇ·á ÁøÀü
      • À¯¸®ÇÑ Á¤ºÎ ±ÔÁ¦¿Í Á¤Ã¥

Á¦4Àå ¾à¹°Àü´Þ ±â±â ¼¼°è ½ÃÀå »ê¾÷ ºÐ¼®

  • Porter's 5 Force ¸ðµ¨
    • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
    • ±¸¸ÅÀÚÀÇ ±³¼··Â
    • ½Å±Ô Âü¿©¾÷üÀÇ À§Çù
    • ´ëüǰÀÇ À§Çù
    • °æÀï ±â¾÷ °£ÀÇ °æÀï °ü°è
  • Porter's 5 Force ¿µÇ⠺м®
  • PEST ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ȯ°æ
    • ¹ý·ü
  • ÁÖ¿ä ÅõÀÚ ±âȸ
  • ÁÖ¿ä ¼º°ø Àü·«
  • COVID-19 ¿µÇ⠺м®
  • ÆÄ±«Àû µ¿Çâ
  • ¾÷°è Àü¹®°¡ÀÇ °üÁ¡
  • ¾Ö³Î¸®½ºÆ®ÀÇ °á·Ð°ú Á¦¾È

Á¦5Àå ¾à¹°Àü´Þ ±â±â ¼¼°è ½ÃÀå : Åõ¿© °æ·Îº°

  • ½ÃÀå ÇöȲ
  • ¾à¹°Àü´Þ ±â±â ¼¼°è ½ÃÀå : Åõ¿© °æ·Îº°, ½ÇÀû - ÀáÀ缺 ºÐ¼®
  • ¾à¹°Àü´Þ ±â±â ¼¼°è ½ÃÀå : Åõ¿© °æ·Îº°, ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
  • ¾à¹°Àü´Þ ±â±â ½ÃÀå, ÇÏÀ§ ºÎ¹® ºÐ¼®
    • ÁÖ»çÁ¦
    • ±¹¼Ò¾à
    • Á¡¾È¾à
    • ±âŸ

Á¦6Àå ¾à¹°Àü´Þ ±â±â ¼¼°è ½ÃÀå : ¿ëµµº°

  • ½ÃÀå ÇöȲ
  • ¾à¹°Àü´Þ ±â±â ¼¼°è ½ÃÀå : ¿ëµµº°, ½ÇÀû - ÀáÀ缺 ºÐ¼®
  • ¾à¹°Àü´Þ ±â±â ¼¼°è ½ÃÀå : ¿ëµµº°, ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
  • ¾à¹°Àü´Þ ±â±â ½ÃÀå, ÇÏÀ§ ºÎ¹®º° ºÐ¼®
    • ¾Ï
    • ½ÉÇ÷°ü
    • ´ç´¢º´
    • °¨¿°Áõ
    • ±âŸ ¿ëµµ

Á¦7Àå ¾à¹°Àü´Þ ±â±â ¼¼°è ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • ½ÃÀå ÇöȲ
  • ¾à¹°Àü´Þ ±â±â ¼¼°è ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°, ½ÇÀû - ÀáÀ缺 ºÐ¼®
  • ¾à¹°Àü´Þ ±â±â ¼¼°è ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°, ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
  • ¾à¹°Àü´Þ ±â±â ½ÃÀå ÇÏÀ§ ºÎ¹® ºÐ¼®
    • º´¿ø
    • ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ
    • ±âŸ ÃÖÁ¾»ç¿ëÀÚ

Á¦8Àå ¾à¹°Àü´Þ ±â±â ¼¼°è ½ÃÀå : Áö¿ªº° ºÐ¼®

  • ÁÖ¿ä ±¹°¡
  • ÁÖ¿ä ½ÅÈï ±¹°¡
  • ¾à¹°Àü´Þ ±â±â ½ÃÀå : Áö¿ªº° ½ÃÀå ÇöȲ
  • ºÏ¹Ì
    • ¹Ì±¹
      • Åõ¿© °æ·Î, ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
      • ¿ëµµ, ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
      • ÃÖÁ¾»ç¿ëÀÚ, ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
    • ij³ª´Ù
  • À¯·´ÀÇ ¾à¹°Àü´Þ ±â±â ½ÃÀå ÇöȲ
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¾à¹°Àü´Þ ±â±â ½ÃÀå ÇöȲ
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ ¾à¹°Àü´Þ ±â±â ½ÃÀå ÇöȲ
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦9Àå °æÀï Á¤º¸

  • ÁÖ¿ä ±â¾÷ SWOT ºÐ¼®
  • ÁÖ¿ä ½ÃÀå Àü·«
  • ±â¾÷ °³¿ä
    • Pfizer Inc.
      • ÁÖ¿ä Á¤º¸
      • °³¿ä
      • À繫(µ¥ÀÌÅÍ °¡¿ë¼º¿¡ µû¶ó ´Ù¸§)
      • Á¦Ç° °³¿ä
    • Novartis AG
    • F Hoffmann-La Roche Ltd
    • Johnson and Johnson Inc
    • Bayer AG
    • Becton, Dickinson and Company
    • Altaris
    • Holozymes Inc.(Antares Pharma Inc.)
    • GlaxoSmithKline PLC
    • Teva Pharmaceutical Industries Ltd

Á¦10Àå Á¶»ç °úÁ¤

  • Á¶»ç °úÁ¤
    • µ¥ÀÌÅÍ ±¤¾÷
    • ºÐ¼®
    • ½ÃÀå ÃßÁ¤
    • °ËÁõ
    • ÃâÆÇ
  • Á¶»ç ¼Ó¼º
  • Á¶»ç °¡Á¤
ksm 23.11.28

Drug discovery devices are technological tools and instruments used in the process of discovering and developing new pharmaceutical drugs. These devices are designed to assist researchers and scientists in various stages of the drug discovery pipeline, from target identification and validation to lead optimization and preclinical testing. The Drug Delivery Devices market is expanding because of factors such as the increasing prevalence of chronic diseases, increasing research and development investment for drug devices, and increasing demand for novel drugs.

The rising prevalence of chronic diseases such as cancer, cardiovascular diseases, and neurological disorders has created a substantial market for drug discovery devices. There is a need for effective drugs to address these diseases, which drives the demand for drug discovery devices. The rising burden of chronic diseases has fueled the need for innovative drugs, leading to increased investment in drug discovery research and the development of sophisticated drug discovery devices. These devices enhance the efficiency and effectiveness of the drug development process, ultimately benefiting patients by providing better treatment options for chronic diseases. The International Diabetes Federation stated that India has an anticipated 74,194.7 thousand cases of diabetes in 2021, and that figure is expected to increase to 92,973.7 thousand cases by 2030. Furthermore, the Robert Wood Johnson Foundation reports that there were 157 million cases of chronic illness in the United States in 2020, with an expected rise to 171 million cases by 2030. Furthermore, the International Agency for Research on Cancer (IARC), estimated that by the year 2040, there would be around 27.5 million new cases across the globe from 1.9 million new cases in the year 2021. Thus, the rising prevalence of the chronic disease across the globe is driving market growth. Moreover, the expansion of strategic initiative implementation and the creation of new products is fueling the market growth. For instance, in March 2021, researchers from Stanford University and the University of North Carolina at Chapel Hill (UNC) created a 3D-printed vaccine patch that they claim offers superior protection to a conventional vaccine shot. The creation of such innovative items is encouraging the use of medicine delivery products and fostering market expansion. In addition, growing initiatives for technological advancement, increasing development of personalized medicine, favorable government regulations and policies are creating opportunities to the market growth. The BLA is planned to be submitted by the end of Q4 2023. The successful launch of this product may provide patients with an alternative option. However, the high cost of drug delivery devices stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Drug Delivery Devices Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the presence of key market players, rising investment in research and development activities, rising prevalence of various diseases and rising drug development activities in the region. Whereas Asia Pacific is projected to have the significant growth owing to factors such as the rising prevalence of chronic diseases, rising healthcare advancement activities, favorable government initiatives for manufacturing drug delivery devices and rising product launches activities in the region.

Major market player included in this report are:

  • Pfizer Inc.
  • Novartis AG
  • F Hoffmann-La Roche Ltd
  • Johnson and Johnson Inc.
  • Bayer AG
  • Becton, Dickinson and Company
  • Altaris
  • Holozymes Inc. (Antares Pharma Inc.)
  • GlaxoSmithKline PLC
  • Teva Pharmaceutical Industries Ltd

Recent Developments in the Market:

  • In June 2022, Gufic Biosciences Ltd. Introduced Dual Chamber Bags, a revolutionary drug delivery method, at competitive pricing. These dual-chamber IV bags include two chambers and are constructed of polypropylene (DEHP free), with an aluminium foil that could peeled off to store unstable medications that need to be reconstituted right before giving them to the patient.
  • In February 2022, The US FDA approved Akeda's TAKHZYRO (lanadelumab-flyo) injectable as a single-dose prefilled syringe (PFS). Using this drug, HAE attacks are be avoided in both adults and children 12 years of age and older.

Global Drug Delivery Devices Market Report Scope:

  • Historical Data - 2020 - 2021
  • Base Year for Estimation - 2022
  • Forecast period - 2023-2030
  • Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered - Route of Administration, Application, End User, Region
  • Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
  • Customization Scope - Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Route of Administration:

  • Injectable
  • Topical
  • Ocular
  • Other Route of Administration

By Application:

  • Cancer
  • Cardiovascular
  • Diabetes
  • Infectious diseases
  • Other Applications

By End User:

  • Hospitals
  • Ambulatory Surgical Centers
  • Other End Users

By Region:

  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Italy
    • ROE
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • RoAPAC
  • Latin America
    • Brazil
    • Mexico
  • Middle East & Africa
    • Saudi Arabia
    • South Africa
    • Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
    • 1.2.1. Drug Delivery Devices Market, by Region, 2020-2030 (USD Billion)
    • 1.2.2. Drug Delivery Devices Market, by Route of Administration, 2020-2030 (USD Billion)
    • 1.2.3. Drug Delivery Devices Market, by Application, 2020-2030 (USD Billion)
    • 1.2.4. Drug Delivery Devices Market, by End User, 2020-2030 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Drug Delivery Devices Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Industry Evolution
    • 2.2.2. Scope of the Study
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Drug Delivery Devices Market Dynamics

  • 3.1. Drug Delivery Devices Market Impact Analysis (2020-2030)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Increasing prevelance of chronic diseases
      • 3.1.1.2. Increasing research and development investment
      • 3.1.1.3. Increasing demand for novel drugs
    • 3.1.2. Market Challenges
      • 3.1.2.1. High Cost of Drug Delivery Devices
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Growing initiatives for technological advancement
      • 3.1.3.2. Increasing development of personalized medicine
      • 3.1.3.3. Favourable government regulations and policies

Chapter 4. Global Drug Delivery Devices Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Porter's 5 Force Impact Analysis
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
    • 4.3.5. Environmental
    • 4.3.6. Legal
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. COVID-19 Impact Analysis
  • 4.7. Disruptive Trends
  • 4.8. Industry Expert Perspective
  • 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Drug Delivery Devices Market, by Route of Administration

  • 5.1. Market Snapshot
  • 5.2. Global Drug Delivery Devices Market by Route of Administration, Performance - Potential Analysis
  • 5.3. Global Drug Delivery Devices Market Estimates & Forecasts by Route of Administration 2020-2030 (USD Billion)
  • 5.4. Drug Delivery Devices Market, Sub Segment Analysis
    • 5.4.1. Injectable
    • 5.4.2. Topical
    • 5.4.3. Ocular
    • 5.4.4. Other Route of Administration

Chapter 6. Global Drug Delivery Devices Market, by Application

  • 6.1. Market Snapshot
  • 6.2. Global Drug Delivery Devices Market by Application, Performance - Potential Analysis
  • 6.3. Global Drug Delivery Devices Market Estimates & Forecasts by Application 2020-2030 (USD Billion)
  • 6.4. Drug Delivery Devices Market, Sub Segment Analysis
    • 6.4.1. Cancer
    • 6.4.2. Cardiovascular
    • 6.4.3. Diabetes
    • 6.4.4. Infectious diseases
    • 6.4.5. Other Applications

Chapter 7. Global Drug Delivery Devices Market, by End User

  • 7.1. Market Snapshot
  • 7.2. Global Drug Delivery Devices Market by End User, Performance - Potential Analysis
  • 7.3. Global Drug Delivery Devices Market Estimates & Forecasts by End User 2020-2030 (USD Billion)
  • 7.4. Drug Delivery Devices Market, Sub Segment Analysis
    • 7.4.1. Hospitals
    • 7.4.2. Ambulatory Surgical Centers
    • 7.4.3. Other End Users

Chapter 8. Global Drug Delivery Devices Market, Regional Analysis

  • 8.1. Top Leading Countries
  • 8.2. Top Emerging Countries
  • 8.3. Drug Delivery Devices Market, Regional Market Snapshot
  • 8.4. North America Drug Delivery Devices Market
    • 8.4.1. U.S. Drug Delivery Devices Market
      • 8.4.1.1. Route of Administration breakdown estimates & forecasts, 2020-2030
      • 8.4.1.2. Application breakdown estimates & forecasts, 2020-2030
      • 8.4.1.3. End User breakdown estimates & forecasts, 2020-2030
    • 8.4.2. Canada Drug Delivery Devices Market
  • 8.5. Europe Drug Delivery Devices Market Snapshot
    • 8.5.1. U.K. Drug Delivery Devices Market
    • 8.5.2. Germany Drug Delivery Devices Market
    • 8.5.3. France Drug Delivery Devices Market
    • 8.5.4. Spain Drug Delivery Devices Market
    • 8.5.5. Italy Drug Delivery Devices Market
    • 8.5.6. Rest of Europe Drug Delivery Devices Market
  • 8.6. Asia-Pacific Drug Delivery Devices Market Snapshot
    • 8.6.1. China Drug Delivery Devices Market
    • 8.6.2. India Drug Delivery Devices Market
    • 8.6.3. Japan Drug Delivery Devices Market
    • 8.6.4. Australia Drug Delivery Devices Market
    • 8.6.5. South Korea Drug Delivery Devices Market
    • 8.6.6. Rest of Asia Pacific Drug Delivery Devices Market
  • 8.7. Latin America Drug Delivery Devices Market Snapshot
    • 8.7.1. Brazil Drug Delivery Devices Market
    • 8.7.2. Mexico Drug Delivery Devices Market
  • 8.8. Middle East & Africa Drug Delivery Devices Market
    • 8.8.1. Saudi Arabia Drug Delivery Devices Market
    • 8.8.2. South Africa Drug Delivery Devices Market
    • 8.8.3. Rest of Middle East & Africa Drug Delivery Devices Market

Chapter 9. Competitive Intelligence

  • 9.1. Key Company SWOT Analysis
    • 9.1.1. Company 1
    • 9.1.2. Company 2
    • 9.1.3. Company 3
  • 9.2. Top Market Strategies
  • 9.3. Company Profiles
    • 9.3.1. Pfizer Inc.
      • 9.3.1.1. Key Information
      • 9.3.1.2. Overview
      • 9.3.1.3. Financial (Subject to Data Availability)
      • 9.3.1.4. Product Summary
      • 9.3.1.5. Recent Developments
    • 9.3.2. Novartis AG
    • 9.3.3. F Hoffmann-La Roche Ltd
    • 9.3.4. Johnson and Johnson Inc
    • 9.3.5. Bayer AG
    • 9.3.6. Becton, Dickinson and Company
    • 9.3.7. Altaris
    • 9.3.8. Holozymes Inc. (Antares Pharma Inc.)
    • 9.3.9. GlaxoSmithKline PLC
    • 9.3.10. Teva Pharmaceutical Industries Ltd

Chapter 10. Research Process

  • 10.1. Research Process
    • 10.1.1. Data Mining
    • 10.1.2. Analysis
    • 10.1.3. Market Estimation
    • 10.1.4. Validation
    • 10.1.5. Publishing
  • 10.2. Research Attributes
  • 10.3. Research Assumption
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦